Key terms

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest RYTM news

Yesterday 6:45am ET Wells Fargo Remains a Buy on Rhythm Pharmaceuticals (RYTM) by TipRanks Apr 16 5:32am ET Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM) by TipRanks Apr 01 8:19am ET Rhythm Pharmaceuticals secures $150M in convertible preferred stock financing by TipRanks Mar 26 6:20am ET Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS) by TipRanks Mar 25 8:15am ET Rhythm announces first patient dosed in Phase 1 trial of RM-718 by TipRanks Feb 23 8:26am ET Rhythm Pharmaceuticals: Expanding Markets and Innovation Fuel Buy Rating Upgrade by TipRanks Feb 23 6:19am ET 3 Best Stocks to Buy Now, 2/23/2024, According to Top Analysts by TipRanks Feb 22 2:25pm ET Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Imcivree Performance and Market Expansion by TipRanks Feb 22 1:17pm ET Stifel ups Rhythm Pharmaceuticals target, calls pullback buying opportunity by TipRanks Feb 22 12:35pm ET Buy Rating Affirmed for Rhythm Pharmaceuticals Amidst Growth Potential Despite Quarterly Sales Variability by TipRanks Feb 22 7:47am ET Buy Rating Affirmed for Rhythm Pharmaceuticals Amid Strong Prescription Growth and Promising Clinical Developments by TipRanks Feb 22 7:28am ET Rhythm Pharmaceuticals announces development plan of setmelanotide by TipRanks Feb 22 7:12am ET Rhythm Pharmaceuticals Announces Upcoming Financial Control Deficiencies by TipRanks Feb 22 7:09am ET Rhythm Pharmaceuticals announces upcoming milestones by TipRanks Feb 22 7:08am ET Rhythm Pharmaceuticals reports Q4 EPS (70c), consensus (70c) by TipRanks Feb 09 8:28am ET Stifel Nicolaus Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM) by TipRanks Feb 09 8:16am ET Buy Rating for Rhythm Pharmaceuticals: Anticipated Growth and Strong Performance Led by IMCIVREE in BBS Market by TipRanks Feb 07 8:15am ET Rhythm Pharmaceuticals announces reimbursement decision in Italy for IMCIVREE by TipRanks Jan 26 11:25am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 26 5:55am ET Buy Rating Reaffirmed for Rhythm Pharmaceuticals Amid Stable Sales Projections and Strong Product Outlook by TipRanks

No recent press releases are available for RYTM

RYTM Financials

1-year income & revenue

Key terms

RYTM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

RYTM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming